Identification
- Generic Name
- Eldecalcitol
- DrugBank Accession Number
- DB05295
- Background
Eldecalcitol (ED-71), a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Eldecalcitol, effectively and safely increased lumbar and hip bone mineral density (BMD) in osteoporotic patients who also received vitamin D3 supplementation.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Eldecalcitol (DB05295)
- Weight
- Average: 490.725
Monoisotopic: 490.36582471 - Chemical Formula
- C30H50O5
- Synonyms
- 1α,25-dihydroxy-2β-(3-hydroxypropoxy)cholecalciferol
- Eldecalcitol
- External IDs
- ED-71
Pharmacology
- Indication
Investigated for use/treatment in osteoporosis.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Eldecalcitol [1a,25-DIHYDROXY-2ß-(3-hydroxypropoxy)vitamin D3] is an analog of 1a,25-dihydroxyvitamin D3 [1,25(OH)2D3], bearing a hydroxypropoxy residue at the 2b position. Eldecalcitol is also effective in increasing bone mass and was able to enhance bone strength in rodents. It binds to the vitamin D receptor (VDR) with less affinity but binds to vitamin D-binding protein with higher affinity than 1,25(OH)2D, showing a long half-life in plasma.
Target Actions Organism UVitamin D3 receptor Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetyldigitoxin The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Eldecalcitol is combined with Acetyldigitoxin. Alfacalcidol The risk or severity of adverse effects can be increased when Alfacalcidol is combined with Eldecalcitol. Aluminum hydroxide The serum concentration of Aluminum hydroxide can be increased when it is combined with Eldecalcitol. Beclomethasone dipropionate The therapeutic efficacy of Eldecalcitol can be decreased when used in combination with Beclomethasone dipropionate. Bendroflumethiazide The risk or severity of hypercalcemia can be increased when Bendroflumethiazide is combined with Eldecalcitol. Benzthiazide The risk or severity of hypercalcemia can be increased when Benzthiazide is combined with Eldecalcitol. Betamethasone The therapeutic efficacy of Eldecalcitol can be decreased when used in combination with Betamethasone. Betamethasone phosphate The therapeutic efficacy of Eldecalcitol can be decreased when used in combination with Betamethasone phosphate. Budesonide The therapeutic efficacy of Eldecalcitol can be decreased when used in combination with Budesonide. Calcifediol The risk or severity of adverse effects can be increased when Calcifediol is combined with Eldecalcitol. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as vitamin d and derivatives. These are compounds containing a secosteroid backbone, usually secoergostane or secocholestane.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Vitamin D and derivatives
- Direct Parent
- Vitamin D and derivatives
- Alternative Parents
- Triterpenoids / Cyclitols and derivatives / Tertiary alcohols / Secondary alcohols / Dialkyl ethers / Primary alcohols / Hydrocarbon derivatives
- Substituents
- Alcohol / Aliphatic homopolycyclic compound / Cyclic alcohol / Cyclitol or derivatives / Dialkyl ether / Ether / Hydrocarbon derivative / Organic oxygen compound / Organooxygen compound / Primary alcohol
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- tetrol, D3 vitamins, hydroxycalciol (CHEBI:73927) / Vitamin D3 and derivatives (LMST03020477)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- I2JP8UE90H
- CAS number
- 104121-92-8
- InChI Key
- FZEXGDDBXLBRTD-AYIMTCTASA-N
- InChI
- InChI=1S/C30H50O5/c1-20(9-6-15-29(3,4)34)24-13-14-25-22(10-7-16-30(24,25)5)11-12-23-19-26(32)28(27(33)21(23)2)35-18-8-17-31/h11-12,20,24-28,31-34H,2,6-10,13-19H2,1,3-5H3/b22-11+,23-12-/t20-,24-,25+,26-,27-,28-,30-/m1/s1
- IUPAC Name
- (1R,2R,3R,5Z)-5-{2-[(1R,3aS,4E,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-2-(3-hydroxypropoxy)-4-methylidenecyclohexane-1,3-diol
- SMILES
- [H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)[C@@H](OCCCO)[C@H](O)C1=C)[C@H](C)CCCC(C)(C)O
References
- General References
- Matsumoto T, Miki T, Hagino H, Sugimoto T, Okamoto S, Hirota T, Tanigawara Y, Hayashi Y, Fukunaga M, Shiraki M, Nakamura T: A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2005 Sep;90(9):5031-6. Epub 2005 Jun 21. [Article]
- External Links
- PubChem Compound
- 6918141
- PubChem Substance
- 175426970
- ChemSpider
- 5293354
- ChEBI
- 73927
- ZINC
- ZINC000003934328
- PDBe Ligand
- ED9
- Wikipedia
- Eldecalcitol
- PDB Entries
- 3wgp
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Osteoporosis 1 1 Completed Prevention Healthy Subjects (HS) 1 1 Recruiting Treatment Osteoporosis 1 Not Available Not Yet Recruiting Not Available Postmenopausal Osteoporosis 1 Not Available Unknown Status Treatment Osteoporosis 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0105 mg/mL ALOGPS logP 5.04 ALOGPS logP 3.67 Chemaxon logS -4.7 ALOGPS pKa (Strongest Acidic) 13.38 Chemaxon pKa (Strongest Basic) -1.3 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 90.15 Å2 Chemaxon Rotatable Bond Count 10 Chemaxon Refractivity 143.54 m3·mol-1 Chemaxon Polarizability 59.7 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.962 Blood Brain Barrier + 0.8035 Caco-2 permeable - 0.5609 P-glycoprotein substrate Substrate 0.8469 P-glycoprotein inhibitor I Inhibitor 0.7612 P-glycoprotein inhibitor II Inhibitor 0.5476 Renal organic cation transporter Non-inhibitor 0.7485 CYP450 2C9 substrate Non-substrate 0.8635 CYP450 2D6 substrate Non-substrate 0.8666 CYP450 3A4 substrate Substrate 0.7426 CYP450 1A2 substrate Non-inhibitor 0.9083 CYP450 2C9 inhibitor Non-inhibitor 0.7833 CYP450 2D6 inhibitor Non-inhibitor 0.934 CYP450 2C19 inhibitor Non-inhibitor 0.8324 CYP450 3A4 inhibitor Non-inhibitor 0.8989 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8498 Ames test Non AMES toxic 0.926 Carcinogenicity Non-carcinogens 0.9245 Biodegradation Not ready biodegradable 0.9862 Rat acute toxicity 3.3673 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9273 hERG inhibition (predictor II) Non-inhibitor 0.5437
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Zinc ion binding
- Specific Function
- Nuclear hormone receptor. Transcription factor that mediates the action of vitamin D3 by controlling the expression of hormone sensitive genes. Recruited to promoters via its interaction with BAZ1B...
- Gene Name
- VDR
- Uniprot ID
- P11473
- Uniprot Name
- Vitamin D3 receptor
- Molecular Weight
- 48288.64 Da
Drug created at November 18, 2007 18:23 / Updated at February 21, 2021 18:51